In a remarkable advancement in the fight against malaria, The Medicines for Malaria Venture (MMV) and Quotient Sciences have initiated a Phase 1 clinical trial for MMV371, a long-acting injectable (LAI) malaria preventive. Conducted with healthy volunteers in Nottingham, UK, this trial represents a
Switzerland has established itself as a global leader in the biotech industry, making significant advancements in areas such as cancer treatment, immunotherapy, gene and cell therapy, and more. With a strong focus on personalized and precision medicine, the Swiss biotech sector thrives on
Clinical trials have long faced significant challenges in enrolling and retaining participants, a problem exacerbated by logistical and engagement difficulties inherent in the clinical trial process. Recent data highlights that up to one-third of trial participants drop out before the studies are
In a significant leap forward for oncology, the U.S. Food and Drug Administration (FDA) has given the green light to Astellas Pharma Inc.'s VYLOY (zolbetuximab-clzb) for treating adults with advanced, unresectable, or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or
Charles River Laboratories has taken a significant stride in the realm of biopharmaceutical research by launching the Retrogenix Non-Human Protein Library. This innovation is particularly designed to help clients assess the off-target interactions of their therapeutics with non-human proteins. The
Respiratory syncytial virus (RSV) has long been a formidable challenge, particularly for infants and older adults. Characterized by cold-like symptoms, RSV can sometimes escalate into severe respiratory conditions necessitating hospitalization. Nearly every child is exposed to RSV by the age of
